Cardiff Oncology, Inc. (CRDF): Price and Financial Metrics

Cardiff Oncology, Inc. (CRDF): $5.34

0.41 (-7.13%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add CRDF to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#276 of 365

in industry

CRDF Price/Volume Stats

Current price $5.34 52-week high $6.42
Prev. close $5.75 52-week low $0.94
Day low $5.19 Volume 864,400
Day high $5.73 Avg. volume 1,667,489
50-day MA $2.88 Dividend yield N/A
200-day MA $1.82 Market Cap 238.58M

CRDF Stock Price Chart Interactive Chart >

CRDF POWR Grades

  • CRDF scores best on the Sentiment dimension, with a Sentiment rank ahead of 94.68% of US stocks.
  • The strongest trend for CRDF is in Growth, which has been heading down over the past 26 weeks.
  • CRDF ranks lowest in Momentum; there it ranks in the 7th percentile.

CRDF Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for CRDF is 0.01 -- better than just 9.09% of US stocks.
  • With a price/sales ratio of 148.6, CARDIFF ONCOLOGY INC has a higher such ratio than 98.08% of stocks in our set.
  • CRDF's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 9.58% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CARDIFF ONCOLOGY INC are ALGS, MRUS, DBVT, HYLN, and CRIS.
  • CRDF's SEC filings can be seen here. And to visit CARDIFF ONCOLOGY INC's official web site, go to www.cardiffoncology.com.

CRDF Valuation Summary

  • In comparison to the median Healthcare stock, CRDF's price/earnings ratio is 105.49% lower, now standing at -1.6.
  • Over the past 201 months, CRDF's EV/EBIT ratio has gone up 72.9.

Below are key valuation metrics over time for CRDF.

Stock Date P/S P/B P/E EV/EBIT
CRDF 2023-12-29 143.7 0.8 -1.6 -1.3
CRDF 2023-12-28 140.9 0.8 -1.6 -1.3
CRDF 2023-12-27 147.6 0.9 -1.7 -1.3
CRDF 2023-12-26 150.4 0.9 -1.7 -1.4
CRDF 2023-12-22 142.8 0.8 -1.6 -1.3
CRDF 2023-12-21 143.7 0.8 -1.6 -1.3

CRDF Growth Metrics

    The 4 year price growth rate now stands at -98.06%.
  • The 3 year cash and equivalents growth rate now stands at 76.98%.
  • Its 5 year revenue growth rate is now at -1.51%.
Over the past 15 months, CRDF's revenue has gone down $4,656.

The table below shows CRDF's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.391 -31.82 -39.473
2022-06-30 0.384 -29.799 -37.815
2022-03-31 0.361 -27.405 -34.129
2021-12-31 0.359 -23.04 -28.315
2021-09-30 0.345255 -20.77394 -25.47011
2021-06-30 0.395656 -18.83417 -23.0537

CRDF's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CRDF has a Quality Grade of D, ranking ahead of 16.71% of graded US stocks.
  • CRDF's asset turnover comes in at 0.004 -- ranking 418th of 682 Pharmaceutical Products stocks.
  • OTIC, AVDL, and CORT are the stocks whose asset turnover ratios are most correlated with CRDF.

The table below shows CRDF's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.004 1 -0.388
2021-03-31 0.004 1 -0.758
2020-12-31 0.007 1 17.949
2020-09-30 0.014 1 22.880
2020-06-30 0.015 1 50.452
2020-03-31 0.028 1 -56.954

CRDF Price Target

For more insight on analysts targets of CRDF, see our CRDF price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.33 Average Broker Recommendation 1.5 (Moderate Buy)

Cardiff Oncology, Inc. (CRDF) Company Bio


Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.


CRDF Latest News Stream


Event/Time News Detail
Loading, please wait...

CRDF Latest Social Stream


Loading social stream, please wait...

View Full CRDF Social Stream

Latest CRDF News From Around the Web

Below are the latest news stories about CARDIFF ONCOLOGY INC that investors may wish to consider to help them evaluate CRDF as an investment opportunity.

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 35th Annual Piper Sandler Healthcare Conference, which is taking place at the Lotte New York Palace in New York from November 28-30, 2023.

Yahoo | November 20, 2023

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results for the third quarter ended September 30, 2023, and provided a business update.

Yahoo | November 2, 2023

We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | October 31, 2023

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on Thursday, November 2 after the close of trading.

Yahoo | October 26, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are worth keeping track of and we're helping with the biggest winners and losers for Wednesday morning!

William White on InvestorPlace | September 27, 2023

Read More 'CRDF' Stories Here

CRDF Price Returns

1-mo 193.41%
3-mo 260.81%
6-mo 284.17%
1-year 223.64%
3-year -41.32%
5-year 42.40%
YTD 260.81%
2023 5.71%
2022 -76.71%
2021 -66.59%
2020 1,350.81%
2019 -60.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!